Emergent BioSolutions Reports Profitability Amid Ongoing Turnaround
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Emergent Biosolutions ( (EBS) ) has provided an update.
On February 26, 2026, Emergent BioSolutions reported its fourth-quarter and full-year 2025 results, showing a sharp turnaround to full-year net income of $52.6 million from a $190.6 million loss in 2024, despite a 29% drop in revenue to $742.9 million. Profitability improved on higher gross and adjusted EBITDA margins, though the fourth quarter remained weak, with revenue down 24% to $148.7 million and a wider net loss of $54.6 million.
Management said the 2025 performance reflects progress on a multi-year turnaround, citing adjusted EBITDA of $205 million, stronger cash flow and reduced leverage. The company advanced its medical countermeasures franchise with over $450 million in contracts, maintained naloxone market leadership with more than $226 million in revenue, executed $24.8 million of share buybacks under a $50 million authorization, made a $100 million voluntary debt payment, completed asset sales, secured new naloxone rights, and prepared a fresh $50 million repurchase plan running from late February 2026 through March 2027.
The most recent analyst rating on (EBS) stock is a Hold with a $13.00 price target. To see the full list of analyst forecasts on Emergent Biosolutions stock, see the EBS Stock Forecast page.
Spark’s Take on EBS Stock
According to Spark, TipRanks’ AI Analyst, EBS is a Neutral.
The score is capped mainly by weak cash flow generation and leverage risk despite improved margins. Offsetting these, the latest earnings call and corporate updates point to better execution with raised guidance and deleveraging progress, while technicals are mixed and valuation appears modest on a low P/E.
To see Spark’s full report on EBS stock, click here.
More about Emergent Biosolutions
Emergent BioSolutions Inc. is a U.S.-based biopharmaceutical company focused on medical countermeasures for public health threats and opioid overdose treatment. Its portfolio includes biodefense vaccines and therapeutics such as anthrax and smallpox products, as well as naloxone nasal sprays NARCAN and KLOXXADO, with a growing emphasis on international markets and multiple durable, profitable business verticals.
Average Trading Volume: 805,255
Technical Sentiment Signal: Buy
Current Market Cap: $575.6M
Learn more about EBS stock on TipRanks’ Stock Analysis page.
